Company valuations
We invite you to examine Pharma Equity Group’s latest valuations. These analyses are an important part of our growth journey and give you insight into our financial health and future prospects. Understanding the value of your investments is critical in a dynamic market.
By reading our valuations, you get a clear overview of how our strategies and initiatives position us for growth and opportunities. It’s a chance to see how our work creates value for the company and strengthens your role as a shareholder.
We value your trust and commitment and look forward to sharing our vision for the future with you. Take a look at our valuations and learn more about how Pharma Equity Group can shape your investment portfolio.
Please take a moment to explore our analyst partners and company valuations listed below.
Danske Bank Equity Research Valuation reports
Danske Bank Equity Research, which became an equity analyst for the PEG stock on March 22, 2024, has spent approximately 3 months on an in-depth analysis of Pharma Equity Group A/S (PEG). In their analysis, they write:
“PEG is a pre-revenue biotech focused on a drug repositioning strategy with six assets in Phase 2. For the key assets, RNX-011 and RNX-051, we see a de-risked NPV per share of DKK 1.11-1.18, both with potential launch in 2028. Given significant clinical and patent risks, we estimate a risk-adjusted fair value of DKK 0.34-0.89 for the group. We see partnering for Phase 3 development before year-end 2025 as crucial for the shares.”
Danske Bank Equity Research values PEG at DKK 0.56 per share in their base case and DKK 0.89 per share in their best case.
Analyst Group (SE) Valuation Reports
Analyst Group is currently following Pharma Equity Group’s share, providing comprehensive analysis and market insights. This coverage reflects the growing interest in our company’s strategic direction and long-term potential in the pharmaceutical sector.
Analyst Group’s detailed reports will keep investors informed about our progress, financial performance, and growth prospects. Their ongoing analysis will enhance transparency and support our commitment to maintaining open communication with our stakeholders.
HC Andersen Capital Valuation Reports
Disclaimer:
Our analyst partners receives payment from Pharma Equity Group A/S for a Digital IR/Corporate Visibility subscription agreement.
Stock information
Press on the link button below to be directed to Pharma Equity Groups’ stock information page on Nasdaq.
Notat om skattemæssig anskaffelsessum ved børsnotering
Note on tax basis upon stock exchange listing
The Danish Tax Authority granted a general permit on June 22, 2022, allowing the exchange of shares in Reponex Pharmaceuticals A/S for shares in Pharma Equity Group A/S to be carried out as a tax-free share exchange. The permit for tax-free share exchange has been published in SKM2022.324.SKTST and can be utilized by both corporate shareholders and individual shareholders. Download the complete note by pressing the button below.